Glycogen Phosphorylase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 63: Line 63:
**[[3e3l]], [[1c50]], [[1bx3]], [[2gpn]], [[1gpb]] – rGP<br />
**[[3e3l]], [[1c50]], [[1bx3]], [[2gpn]], [[1gpb]] – rGP<br />
**[[1abb]] – rGP + modified cofactor<br />
**[[1abb]] – rGP + modified cofactor<br />
-
**[[1z8d]] – hGP + AMP + glucose - human<br />
+
**[[1z8d]] – hGP muscle form + AMP + glucose - human<br />
-
**[[1fa9]] – hGP + AMP<br />
+
**[[5iko]] – hGP brain form + PLP<br />
 +
**[[5ikp]] – hGP brain form + PLP + AMP<br />
 +
**[[1fa9]] – hGP liver form + AMP<br />
**[[1ygp]] – GP + phosphate – yeast
**[[1ygp]] – GP + phosphate – yeast
Line 99: Line 101:
**[[1p29]], [[1p2b]], [[1p2d]], [[1p2g]] - rGP + cyclodextrin derivative inhibitor<br />
**[[1p29]], [[1p2b]], [[1p2d]], [[1p2g]] - rGP + cyclodextrin derivative inhibitor<br />
**[[1lwn]], [[1lwo]] – rGP + hypoglycaemic drug<br />
**[[1lwn]], [[1lwo]] – rGP + hypoglycaemic drug<br />
-
**[[2gpa]], [[2amv]], [[3amv]], [[3zcp]], [[3zcq]], [[3zcr]], [[3zcs]], [[3zct]], [[3zcu]], [[3zcv]] - rGP + antidiabetic drug<br />
+
**[[2gpa]], [[2amv]], [[3amv]], [[3zcp]], [[3zcq]], [[3zcr]], [[3zcs]], [[3zct]], [[3zcu]], [[3zcv]], [[4yi3]], [[4yi5]], [[4yua]], [[4z5x]] - rGP muscle form + antidiabetic drug<br />
 +
**[[5jtt]], [[5jtu]] - rGP muscle form + imidazole derivative<br />
 +
**[[5lremuscle form ]] - rGP muscle form + triazole derivative<br />
**[[4mho]], [[4mhs]], [[4mi3]], [[4mi6]], [[4mi9]], [[4mic]] - rGP + glucopyranosyl derivative<br />
**[[4mho]], [[4mhs]], [[4mi3]], [[4mi6]], [[4mi9]], [[4mic]] - rGP + glucopyranosyl derivative<br />
**[[4mra]] - rGP + quercetin<br />
**[[4mra]] - rGP + quercetin<br />

Revision as of 09:37, 1 June 2017

Contents

Introduction

Glycogen phosphorylase catalyzes the hydrolysis of glycogen to generate glucose-1-phosphate and shortened glycogen molecule and is considered the rate limiting step in the degradation of glycogen[1]. It is a part of the glucosyltransferase family and acts on the α-1,4-glycosidic linkage; the phosphorylase comes to a standstill 4 residues from an α-1,6-branchpoint, where debranching enzyme takes over [2]. The glucose-1-phophate is then further degraded via the pathway of glycolysis. Studies have found that mammals have liver, muscle and brain isoforms of phosphorylase but it is found among all species; muscle glycogen phosphorylase is present to degrade glycogen to forms of energy by means of glycolysis during muscle contractions and liver glycogen is present to regulate the blood glucose levels within the blood [2][3]. See also Glycogen Metabolism & Gluconeogenesis.


PDB ID 1ygp

Drag the structure with the mouse to rotate

3D structures of glycogen phosphorylase

Updated on 01-June-2017

Additional Resources

For additional information, see: Carbohydrate Metabolism

References

  1. 1.0 1.1 1.2 Kristiansen M, Andersen B, Iversen LF, Westergaard N. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. J Med Chem. 2004 Jul 1;47(14):3537-45. PMID:15214781 doi:10.1021/jm031121n
  2. 2.0 2.1 Roach PJ. Glycogen and its metabolism. Curr Mol Med. 2002 Mar;2(2):101-20. PMID:11949930
  3. 3.0 3.1 3.2 3.3 Palm D, Klein HW, Schinzel R, Buehner M, Helmreich EJM. The role of pyridoxal 5’-phosphate in glycogen phosphorylase catalysis. Biochemistry. 1990 Feb 6; 29(5):1099-1107.
  4. 4.0 4.1 4.2 4.3 4.4 Barford D, Hu SH, Johnson LN. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. J Mol Biol. 1991 Mar 5;218(1):233-60. PMID:1900534
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Fletterick RJ, Sprang SR. Glycogen phosphorylase Structures and function. Accounts of Chemical Research. 1982 Nov; 15(11):361-369.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 Johnson LH. Glycogen Phosphorylase: Control by phosphorylation and allosteric effectors. The FASEB Journal. 1992 March;6:2274-2282.
Personal tools